RESUMO
BACKGROUND: Alitretinoin (9-cis-retinoic acid, Toctino(®) ) has been marketed recently for oral therapy for chronic hyperkeratotic hand eczema. As alitretinoin is highly lipophilic and metabolized mainly in the liver, it is currently considered to be contraindicated in patients with liver disease. However, the pharmacokinetics and metabolism of alitretinoin have not been studied in these patients. OBJECTIVES: To study the single-dose pharmacokinetics and metabolism of alitretinoin and its metabolites in patients with cirrhosis following oral administration. METHODS: Eight patients with cirrhosis and eight matched volunteer healthy controls were given a single 30-mg oral dose of alitretinoin. Blood and urine samples were collected during the following 24-h study period. Samples were analysed for alitretinoin and for known metabolites using reverse-phase high-performance liquid chromatography. The pharmacokinetics were then evaluated using standard noncompartmental models. RESULTS: No significant differences were found between healthy controls and patients with cirrhosis when analysing the pharmacokinetic parameters of alitretinoin and its metabolites. Thus, the mean half-lives of alitretinoin were 5·3 and 5·6 h (P = 0.733) and the oral clearances were 1·92 and 1·39 L h(-1) kg(-1) (P = 0·243) in the patient group and the healthy control group, respectively. CONCLUSIONS: The metabolism and pharmacokinetics of alitretinoin following oral administration of the recommended dose of 30 mg for the treatment of severe hand eczema were similar in patients with cirrhosis and in healthy controls. If indicated, alitretinoin can be used in these patients with careful and close monitoring.
Assuntos
Fármacos Dermatológicos/farmacocinética , Cirrose Hepática/metabolismo , Tretinoína/farmacocinética , Administração Oral , Idoso , Alitretinoína , Área Sob a Curva , Fármacos Dermatológicos/administração & dosagem , Eczema/tratamento farmacológico , Feminino , Dermatoses da Mão/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Tretinoína/administração & dosagemRESUMO
The ZnT3 zinc transporter is uniquely expressed in cortical glutamatergic synapses where it organizes zinc release into the synaptic cleft and mediates beta-amyloid deposition in transgenic mice. We studied the association of zinc in plaques in relation to cytoarchitectural zinc localization in the APP/PS1 transgenic mouse model of Alzheimer's disease. The effects of low dietary zinc for 3 months upon brain pathology were also studied. We determined that synaptic zinc distribution within cortical layers is paralleled by amyloid burden, which is heaviest for both in layers 2-3 and 5. ZnT3 immunoreactivity is prominent in dystrophic neurites within amyloid plaques. Low dietary zinc caused a significant 25% increase in total plaque volume in Alzheimer's mice using stereological measures. The level of oxidized proteins in brain tissue did not changed in animals on a zinc-deficient diet compared with controls. No obvious changes were observed in the autometallographic pattern of zinc-enriched terminals in the neocortex or in the expression levels of zinc transporters, zinc importers or metallothioneins. A small decrease in plasma zinc induced by the low-zinc diet was consistent with the subclinical zinc deficiency that is common in older human populations. While the mechanism remains uncertain, our findings indicate that subclinical zinc deficiency may be a risk factor for Alzheimer's pathology.
Assuntos
Doença de Alzheimer/metabolismo , Córtex Cerebral/metabolismo , Placa Amiloide/metabolismo , Zinco/deficiência , Zinco/metabolismo , Doença de Alzheimer/genética , Doença de Alzheimer/fisiopatologia , Peptídeos beta-Amiloides/biossíntese , Precursor de Proteína beta-Amiloide/genética , Animais , Córtex Cerebral/patologia , Córtex Cerebral/fisiopatologia , Feminino , Alimentos Formulados , Masculino , Camundongos , Camundongos Transgênicos , Necessidades Nutricionais , Placa Amiloide/patologia , Presenilina-1/genética , Fatores de RiscoRESUMO
The incidence of Alzheimer's disease (AD) is increasing. Major risk factors for AD are advancing age and diabetes. Lately, obesity has been associated with an increased risk of dementia. Obese and diabetic individuals are prone to decreased circulating levels of zinc, reducing the amount of zinc available for crucial intracellular processes. In the brain, zinc co-localizes with glutamate in synaptic vesicles, and modulates NMDA receptor activity. Intracellular zinc is involved in apoptosis and fluctuations in cytoplasmic Zn(2+) affect modulation of intracellular signaling. The ZNT and ZIP proteins participate in intracellular zinc homeostasis. Altered expression of zinc-regulatory proteins has been described in AD patients. Using microarray data from human frontal cortex (BrainCloud), this study investigates expression of the SCLA30A (ZNT) and SCLA39A (ZIP) families of genes in a Caucasian and African-American sample of 145 neurologically and psychiatrically normal individuals. Expression of ZNT3 and ZNT4 were significantly reduced with increasing age, whereas expression of ZIP1, ZIP9 and ZIP13 were significantly increased. Increasing body mass index (BMI) correlated with a significant reduction in ZNT1 expression similar to what is seen in the early stages of AD. Increasing BMI also correlated with reduced expression of ZNT6. In conclusion, we found that the expression of genes that regulate intracellular zinc homeostasis in the human frontal cortex is altered with increasing age and affected by increasing BMI. With the increasing rates of obesity throughout the world, these findings warrant continuous scrutiny of the long-term consequences of obesity on brain function and the development of neurodegenerative diseases.
Assuntos
Doença de Alzheimer/genética , Negro ou Afro-Americano/genética , Proteínas de Transporte/genética , Proteínas de Ligação a DNA/genética , Lobo Frontal/metabolismo , Expressão Gênica/genética , Obesidade/complicações , Obesidade/genética , Fatores de Transcrição/genética , População Branca/genética , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/fisiopatologia , Índice de Massa Corporal , Proteínas de Transporte de Cátions/genética , Bases de Dados Genéticas , Feminino , Homeostase/genética , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/fisiologia , Pessoa de Meia-Idade , Obesidade/fisiopatologia , RNA Mensageiro/genética , Fatores de Risco , Estatística como Assunto , Zinco/metabolismo , Fator MTF-1 de TranscriçãoRESUMO
The thyroid status of 317 patients treated with radioactive iodine between 1951 and December 1971 was investigated. Information was obtained on 236 patients and hypothyroidism, either treated or untreated, was present in 48 percent of women and 37 percent of men at mean follow-up intervals of 5.5 and 4.4 years respectively. Ninety-four of the 241 patients still alive were assessed personally by clinical examination and serum thyroxine assay, and 10 were found to have previously undiagnosed hypothyroidism. Seven of these patients had symptoms and in five these symptonms were the cause of significant distress. The importance of undertaking a long term review programme following radioactive iodine therapy is emphasised.
Assuntos
Hipotireoidismo/etiologia , Radioisótopos do Iodo/efeitos adversos , Radioterapia/efeitos adversos , Adenoma/radioterapia , Adulto , Idoso , Feminino , Seguimentos , Doença de Graves/radioterapia , Humanos , Hipertireoidismo/radioterapia , Hipotireoidismo/epidemiologia , Doença Iatrogênica , Masculino , Pessoa de Meia-Idade , Nova Zelândia , Neoplasias da Glândula Tireoide/radioterapiaRESUMO
The authors present an account on radical resections of the rectum in 73 patients during 1991-1995. A radical operation with excision of the mesorectum was performed 69 times, local excisions 4 times. Five-year survival was recorded in 57.90% patients, local relapses were recorded in 10.14% patients. Remote metastases or generalization of the disease was found in 18.84% patients. Adjuvant treatment was administered to 74% patients.
Assuntos
Carcinoma/cirurgia , Neoplasias Retais/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/mortalidade , Feminino , Humanos , Excisão de Linfonodo , Masculino , Pessoa de Meia-Idade , Neoplasias Retais/mortalidade , Taxa de SobrevidaRESUMO
BACKGROUND AND PURPOSE: Introducing the calcineurin inhibitors cyclosporin (CsA) and tacrolimus (Tac) has improved the outcome of organ transplants, but complications such as new onset diabetes mellitus after transplantation (NODAT) decrease survival rates. EXPERIMENTAL APPROACH: We sought, in a beta-cell culture model, to elucidate the pathogenic mechanisms behind NODAT and the relative contribution of the calcineurin inhibitors. INS-1E cells were incubated at basal and stimulatory glucose concentrations, while exposed to pharmacologically relevant doses of CsA, Tac and vehicle for 6 or 24 h. RESULTS: Tac inhibited basal (P < 0.05), but not glucose-stimulated insulin secretion (GSIS) after 6 h of exposure. After 24 h, both agents inhibited basal and GSIS (P < 0.05). Calcineurin phosphatase activity was decreased by both drugs during all conditions. Apoptosis was only seen with CsA treatment, which also induced a slight suppression of calcineurin and insulin mRNA, as well as increased levels of the sterol receptor element binding protein (SREBP)-1c, a transcription factor thought to suppress genes essential for beta-cell function and induce insulin resistance. Expression levels of nuclear factor of activated T-cells (NFAT)-c1, -c2, -c3 and -c4 were not decreased notably by either drug. CONCLUSIONS AND IMPLICATIONS: Tac had acute inhibitory effects on basal insulin secretion, but prolonged exposure (24 h) to Tac or CsA revealed similar suppression of insulin secretion. These prolonged effects were mirrored by a total inhibition of calcineurin activity in beta-cells. CsA showed greater inhibition of beta-cell survival and transcriptional markers, essential for beta-cell function.
Assuntos
Ciclosporina/farmacologia , Imunossupressores/farmacologia , Insulina/metabolismo , Ilhotas Pancreáticas/efeitos dos fármacos , Tacrolimo/farmacologia , Animais , Sequência de Bases , Calcineurina/metabolismo , Inibidores de Calcineurina , Linhagem Celular , Primers do DNA , Ensaio de Imunoadsorção Enzimática , Insulina/genética , Resistência à Insulina , Secreção de Insulina , Ilhotas Pancreáticas/metabolismo , Fatores de Transcrição NFATC/metabolismo , Reação em Cadeia da Polimerase , RNA Mensageiro/genética , Ratos , Transdução de Sinais/efeitos dos fármacosRESUMO
Investigation of gene expression is a developing area with several methods available. One method is quantitative PCR. A major pitfall in quantitative PCR is the normalisation procedure of the gene expression. Many experiments include a housekeeping gene, some use RNA concentration, and others use a geometric mean of several internal, stably expressed genes. This study demonstrates that real-time-PCR results differ with varying housekeeping genes and analysis protocols when applied to insulin-secreting INS-1E cells derived from the pancreas and stimulated by DEDTC (diethyldithiocarbamate, a zinc chelator) and GLP-1.
Assuntos
Perfilação da Expressão Gênica , Regulação da Expressão Gênica/fisiologia , Células Secretoras de Insulina/fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Animais , Linhagem Celular , Quelantes/farmacologia , Ditiocarb/análogos & derivados , Ditiocarb/farmacologia , Perfilação da Expressão Gênica/métodos , Perfilação da Expressão Gênica/normas , Humanos , Insulina/metabolismo , Secreção de Insulina , Células Secretoras de Insulina/citologia , Reprodutibilidade dos Testes , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/normasRESUMO
Zinc in beta-cell secretory vesicles is essential for insulin hexamerization, and tight vesicular zinc regulation is mandatory. Little is known about zinc ion fluxes across the secretory vesicle membrane and the influence of changes in the extracellular environment on vesicular zinc. Our study aim was to investigate the effect of acute and chronic exposure to various glucose concentrations on zinc in secretory vesicles, the relation between zinc and insulin, and the presence of two zinc transporters, ZnT1 and ZnT4, in INS-1E cells. Zinc ions were demonstrated and semi-quantified using zinc-sulfide autometallography. Insulin content and secreted insulin were measured. Measurements were made on INS-1E cells after exposure to 2.0, 6.6, 16.7, and 24.6 mmol/l glucose for 1, 24, and 96 hours. 1h: Increasing glucose resulted in no changes in intravesicular zinc ions at 2, and 24.6 mmol/l glucose, but a slight increase at 16.7 mmol/l glucose. 24 and 96 h: Increasing glucose led to decreased vesicular zinc ion content accompanied by a decrease in insulin content. ZnT1 and ZnT4 were present in the cytoplasm. Our results demonstrate that intra-vesicular zinc ions respond to changes in the extra-cellolar glucose concentration, especially during chronic high glucose concentrations, where the content of vesicular zinc ions decreases.
Assuntos
Glucose/farmacologia , Ilhotas Pancreáticas/efeitos dos fármacos , Ilhotas Pancreáticas/metabolismo , Zinco/metabolismo , Animais , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Insulina/metabolismo , Secreção de Insulina , Insulinoma , Neoplasias Pancreáticas , Ratos , Coloração e RotulagemRESUMO
This report describes a case of blunt abdominal trauma in which a deep congenital fissure in the superior border of the spleen led to the preoperative scintigraphic diagnosis of a splenic hematoma. The frequency of splenic notches of this magnitude is low but significant, hence anatomical variation should be considered in the differential diagnosis of scintigraphic defects.
Assuntos
Hematoma/diagnóstico , Cintilografia , Baço/anormalidades , Esplenopatias/diagnóstico , Adolescente , Diagnóstico Diferencial , Humanos , MasculinoRESUMO
Thirty-two elderly domestic shorthaired cats (mean age 12.9 years) were treated with radioiodine (131I). The dose of 131I administered ranged from 39 mBq to 134 mBq. Twenty-eight cats became euthyroid after treatment, one became hypothyroid and three remained hyperthyroxaemic. Two of the hyperthyroxaemic cats were successfully re-treated with 131I. Five cats died from concurrent diseases within one year of treatment. The administration of a dose of 131I selected by assessing the severity of the clinical signs, the size of the thyroid gland(s) and the serum level of thyroxine was an effective treatment for hyperthyroidism.